Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome

摘要: Alterations of the epidermal growth factor receptor (EGFR) can be observed in a significant subset esophageal adenocarcinomas (EACs), and targeted therapy against EGFR may become an interesting approach for treatment these tumors. Mutations KRAS, NRAS, BRAF, phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) deregulation PTEN expression influence responsiveness anti-EGFR colorectal carcinomas. We investigated prevalence events collection 117 primary resected EACs, correlated findings with amplification, determined their clinicopathologic impact. KRAS mutations were detected 4 (3%) tumors (3× G12D 1 G12V mutation). One tumor had PIK3CA E545K mutation. Neither NRAS nor BRAF detected. Sixteen (14%) cases negative expression, by immunohistochemistry. Loss was predominantly advanced stages (P = .004). There no association between status. associated shorter overall disease-free survival < .001 each) also independent prognostic multivariate analysis .015). status impact this case collection. In summary, loss EAC is aggressive phenotype. Therefore, useful as biomarker. contrast, RAS/RAF/PIK3CA appear only very rarely, if at all, EAC. A possible predictive role warrants further investigations, whereas determination have minor context.